<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>79(5)</volume><submitter>Perera KS</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>Cryptogenic strokes constitute approximately 40% of ischemic strokes in young adults, and most meet criteria for the embolic stroke of undetermined source (ESUS). Two randomized clinical trials, NAVIGATE ESUS and RESPECT ESUS, showed a high rate of stroke recurrence in older adults with ESUS but the prognosis and prognostic factors among younger individuals with ESUS is uncertain.&lt;h4>Objective&lt;/h4>To determine rates of and factors associated with recurrent ischemic stroke and death and new-onset atrial fibrillation (AF) among young adults.&lt;h4>Design, setting, and participants&lt;/h4>This multicenter longitudinal cohort study with enrollment from October 2017 to October 2019 and a mean follow-up period of 12 months ending in October 2020 included 41 stroke research centers in 13 countries. Consecutive patients 50 years and younger with a diagnosis of ESUS were included. Of 576 screened, 535 participants were enrolled after 1 withdrew consent, 41 were found to be ineligible, and 2 were excluded for other reasons. The final follow-up visit was completed by 520 patients.&lt;h4>Main outcomes and measures&lt;/h4>Recurrent ischemic stroke and/or death, recurrent ischemic stroke, and prevalence of patent foramen ovale (PFO).&lt;h4>Results&lt;/h4>The mean (SD) age of participants was 40.4 (7.3) years, and 297 (56%) participants were male. The most frequent vascular risk factors were tobacco use (240 patients [45%]), hypertension (118 patients [22%]), and dyslipidemia (109 patients [20%]). PFO was detected in 177 participants (50%) who had transthoracic echocardiograms with bubble studies. Following initial ESUS, 468 participants (88%) were receiving antiplatelet therapy, and 52 (10%) received anticoagulation. The recurrent ischemic stroke and death rate was 2.19 per 100 patient-years, and the ischemic stroke recurrence rate was 1.9 per 100 patient-years. Of the recurrent strokes, 9 (64%) were ESUS, 2 (14%) were cardioembolic, and 3 (21%) were of other determined cause. AF was detected in 15 participants (2.8%; 95% CI, 1.6-4.6). In multivariate analysis, the following were associated with recurrent ischemic stroke: history of stroke or transient ischemic attack (hazard ratio, 5.3; 95% CI, 1.8-15), presence of diabetes (hazard ratio, 4.4; 95% CI, 1.5-13), and history of coronary artery disease (hazard ratio, 10; 95% CI, 4.8-22).&lt;h4>Conclusions and relevance&lt;/h4>In this large cohort of young adult patients with ESUS, there was a relatively low rate of subsequent ischemic stroke and a low frequency of new-onset AF. Most recurrent strokes also met the criteria for ESUS, suggesting the need for future studies to improve our understanding of the underlying stroke mechanism in this population.</pubmed_abstract><journal>JAMA neurology</journal><pagination>450-458</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8922202</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source: The Young ESUS Longitudinal Cohort Study.</pubmed_title><pmcid>PMC8922202</pmcid><pubmed_authors>D'Anna L</pubmed_authors><pubmed_authors>Wharton C</pubmed_authors><pubmed_authors>Kallmuenzer B</pubmed_authors><pubmed_authors>Young ESUS Investigators</pubmed_authors><pubmed_authors>Francisco Arenillas J</pubmed_authors><pubmed_authors>Naqvi A</pubmed_authors><pubmed_authors>Coutts SB</pubmed_authors><pubmed_authors>Koehn J</pubmed_authors><pubmed_authors>Rezania F</pubmed_authors><pubmed_authors>Mackey E</pubmed_authors><pubmed_authors>Malik A</pubmed_authors><pubmed_authors>Burn M</pubmed_authors><pubmed_authors>Taylor A</pubmed_authors><pubmed_authors>Pikula A</pubmed_authors><pubmed_authors>Pujol Lereis V</pubmed_authors><pubmed_authors>Perera K</pubmed_authors><pubmed_authors>Wijeratne T</pubmed_authors><pubmed_authors>Hankey GJ</pubmed_authors><pubmed_authors>Mazzon E</pubmed_authors><pubmed_authors>Markus H</pubmed_authors><pubmed_authors>Maamari B</pubmed_authors><pubmed_authors>Signh R</pubmed_authors><pubmed_authors>Gluszkiewicz M</pubmed_authors><pubmed_authors>Xu J</pubmed_authors><pubmed_authors>Mikulik R</pubmed_authors><pubmed_authors>Seidel G</pubmed_authors><pubmed_authors>Detmar K</pubmed_authors><pubmed_authors>Kleinig T</pubmed_authors><pubmed_authors>Bojaryn U</pubmed_authors><pubmed_authors>Rodriguez Lucci F</pubmed_authors><pubmed_authors>Renouf A</pubmed_authors><pubmed_authors>Fabregas JM</pubmed_authors><pubmed_authors>Arauz A</pubmed_authors><pubmed_authors>Dossi D</pubmed_authors><pubmed_authors>Karlinski M</pubmed_authors><pubmed_authors>Lee S</pubmed_authors><pubmed_authors>Soledad Rodriguez M</pubmed_authors><pubmed_authors>Weerathunga J</pubmed_authors><pubmed_authors>Buckley C</pubmed_authors><pubmed_authors>Elyas S</pubmed_authors><pubmed_authors>Bathula R</pubmed_authors><pubmed_authors>Ferdinand P</pubmed_authors><pubmed_authors>Pretorius M</pubmed_authors><pubmed_authors>Pico F</pubmed_authors><pubmed_authors>Kelly E</pubmed_authors><pubmed_authors>Maud A</pubmed_authors><pubmed_authors>Bhandari M</pubmed_authors><pubmed_authors>Stotts G</pubmed_authors><pubmed_authors>Javier Alet M</pubmed_authors><pubmed_authors>Cheng A</pubmed_authors><pubmed_authors>Veltkamp RC</pubmed_authors><pubmed_authors>Field T</pubmed_authors><pubmed_authors>Redgrave J</pubmed_authors><pubmed_authors>Rashed K</pubmed_authors><pubmed_authors>Bader J</pubmed_authors><pubmed_authors>Tuetuencue S</pubmed_authors><pubmed_authors>Ziomek M</pubmed_authors><pubmed_authors>Lutsep H</pubmed_authors><pubmed_authors>Goldlin M</pubmed_authors><pubmed_authors>Olavarria V</pubmed_authors><pubmed_authors>Meseguer E</pubmed_authors><pubmed_authors>Perera KS</pubmed_authors><pubmed_authors>Kozera D</pubmed_authors><pubmed_authors>Jung S</pubmed_authors><pubmed_authors>Cohen D</pubmed_authors><pubmed_authors>Majid A</pubmed_authors><pubmed_authors>Meinel T</pubmed_authors><pubmed_authors>Ameriso S</pubmed_authors><pubmed_authors>Ahmad N</pubmed_authors><pubmed_authors>Vynckier J</pubmed_authors><pubmed_authors>Hart RG</pubmed_authors><pubmed_authors>Hill M</pubmed_authors><pubmed_authors>Obaid M</pubmed_authors><pubmed_authors>Halse O</pubmed_authors><pubmed_authors>Rosales J</pubmed_authors><pubmed_authors>Toni D</pubmed_authors><pubmed_authors>Coutts S</pubmed_authors><pubmed_authors>Tse D</pubmed_authors><pubmed_authors>Sethi P</pubmed_authors><pubmed_authors>Roeder S</pubmed_authors><pubmed_authors>Lindert R</pubmed_authors><pubmed_authors>Marti-Fabregas J</pubmed_authors><pubmed_authors>Nayar S</pubmed_authors><pubmed_authors>Bowring A</pubmed_authors><pubmed_authors>Sen S</pubmed_authors><pubmed_authors>Harvey J</pubmed_authors><pubmed_authors>de Sa Boasquevisque D</pubmed_authors><pubmed_authors>Czlonkowska A</pubmed_authors><pubmed_authors>Roffe C</pubmed_authors><pubmed_authors>Arnold M</pubmed_authors><pubmed_authors>Gunathilagan G</pubmed_authors><pubmed_authors>Teleg E</pubmed_authors><pubmed_authors>Basson M</pubmed_authors><pubmed_authors>Harkness K</pubmed_authors><pubmed_authors>Randus I</pubmed_authors><pubmed_authors>Haeusler KG</pubmed_authors><pubmed_authors>Nolte C</pubmed_authors><pubmed_authors>Gomis M</pubmed_authors><pubmed_authors>Rao-Melacini P</pubmed_authors><pubmed_authors>Collas D</pubmed_authors><pubmed_authors>Veronica Marroquin M</pubmed_authors><pubmed_authors>Dutta D</pubmed_authors><pubmed_authors>Munoz L</pubmed_authors><pubmed_authors>Abano N</pubmed_authors><pubmed_authors>Menon N</pubmed_authors><pubmed_authors>Brola W</pubmed_authors><pubmed_authors>Ali Sheikh A</pubmed_authors><pubmed_authors>Ali A</pubmed_authors><pubmed_authors>Birnbaum L</pubmed_authors><pubmed_authors>Veltkamp R</pubmed_authors><pubmed_authors>Ameriso SF</pubmed_authors><pubmed_authors>Banerjee S</pubmed_authors><pubmed_authors>Gomez Schneider M</pubmed_authors><pubmed_authors>Smith E</pubmed_authors><pubmed_authors>Cortijo Garcia E</pubmed_authors><pubmed_authors>Chembala J</pubmed_authors><pubmed_authors>Pablo Povedano G</pubmed_authors><pubmed_authors>Horvath T</pubmed_authors><pubmed_authors>Warburton E</pubmed_authors><pubmed_authors>Mandzia J</pubmed_authors><pubmed_authors>Guyler P</pubmed_authors><pubmed_authors>Macha K</pubmed_authors><pubmed_authors>Geran R</pubmed_authors><pubmed_authors>Field TS</pubmed_authors><pubmed_authors>Arauz Gongora AA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source: The Young ESUS Longitudinal Cohort Study.</name><description>&lt;h4>Importance&lt;/h4>Cryptogenic strokes constitute approximately 40% of ischemic strokes in young adults, and most meet criteria for the embolic stroke of undetermined source (ESUS). Two randomized clinical trials, NAVIGATE ESUS and RESPECT ESUS, showed a high rate of stroke recurrence in older adults with ESUS but the prognosis and prognostic factors among younger individuals with ESUS is uncertain.&lt;h4>Objective&lt;/h4>To determine rates of and factors associated with recurrent ischemic stroke and death and new-onset atrial fibrillation (AF) among young adults.&lt;h4>Design, setting, and participants&lt;/h4>This multicenter longitudinal cohort study with enrollment from October 2017 to October 2019 and a mean follow-up period of 12 months ending in October 2020 included 41 stroke research centers in 13 countries. Consecutive patients 50 years and younger with a diagnosis of ESUS were included. Of 576 screened, 535 participants were enrolled after 1 withdrew consent, 41 were found to be ineligible, and 2 were excluded for other reasons. The final follow-up visit was completed by 520 patients.&lt;h4>Main outcomes and measures&lt;/h4>Recurrent ischemic stroke and/or death, recurrent ischemic stroke, and prevalence of patent foramen ovale (PFO).&lt;h4>Results&lt;/h4>The mean (SD) age of participants was 40.4 (7.3) years, and 297 (56%) participants were male. The most frequent vascular risk factors were tobacco use (240 patients [45%]), hypertension (118 patients [22%]), and dyslipidemia (109 patients [20%]). PFO was detected in 177 participants (50%) who had transthoracic echocardiograms with bubble studies. Following initial ESUS, 468 participants (88%) were receiving antiplatelet therapy, and 52 (10%) received anticoagulation. The recurrent ischemic stroke and death rate was 2.19 per 100 patient-years, and the ischemic stroke recurrence rate was 1.9 per 100 patient-years. Of the recurrent strokes, 9 (64%) were ESUS, 2 (14%) were cardioembolic, and 3 (21%) were of other determined cause. AF was detected in 15 participants (2.8%; 95% CI, 1.6-4.6). In multivariate analysis, the following were associated with recurrent ischemic stroke: history of stroke or transient ischemic attack (hazard ratio, 5.3; 95% CI, 1.8-15), presence of diabetes (hazard ratio, 4.4; 95% CI, 1.5-13), and history of coronary artery disease (hazard ratio, 10; 95% CI, 4.8-22).&lt;h4>Conclusions and relevance&lt;/h4>In this large cohort of young adult patients with ESUS, there was a relatively low rate of subsequent ischemic stroke and a low frequency of new-onset AF. Most recurrent strokes also met the criteria for ESUS, suggesting the need for future studies to improve our understanding of the underlying stroke mechanism in this population.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2026-05-09T22:26:40.963Z</modification><creation>2025-02-18T22:34:36.812Z</creation></dates><accession>S-EPMC8922202</accession><cross_references><pubmed>35285869</pubmed><doi>10.1001/jamaneurol.2022.0048</doi></cross_references></HashMap>